|
|
Latest Pancreatic Cancer News
Gemzar plus Avastin Does Not Improve Survival in Advanced Pancreatic Cancer (7/14/2010)
Results from a recent Phase III trial indicate that the addition of the targeted therapy Avastin® (bevacizumab) to the chemotherapy drug Gemzar® (gemcitabine) does not improve survival in advanced pancreatic cancer.
High Circulating Vitamin D Levels Don’t Reduce Risk of Less Common Cancers (7/12/2010)
High levels of vitamin D in the bloodstream do not appear to reduce the risk of seven less common cancers: endometrial, esophageal, stomach, ovarian, pancreatic, kidney, and non-Hodgkin’s lymphoma.
Afinitor Delays Progression of Advanced Pancreatic Neuroendocrine Tumors (7/8/2010)
In a recent Phase III trial, the targeted therapy Afinitor® (everolimus) more than doubled progression-free survival time among patients with advanced pancreatic neuroendocrine tumors (NET).
Improved Survival in Metastatic Pancreatic Cancer (6/24/2010)
It appears that the chemotherapy combination known as FOLFIRINOX may improve survival in metastatic pancreatic cancer over a current standard-of-care, Gemzar® (gemcitabine).
AMG 479 Produces Promising Results in Metastatic Pancreatic Cancer (6/7/2010)
According to the results of a Phase II clinical trial, treatment of metastatic pancreatic cancer with a combination of AMG 479 and Gemzar® (gemcitabine) resulted in better progression-free and overall survival than treatment with Gemzar alone. These results were presented at the 2010 annual meeting of the American Society of Clinical Oncology.
Pancreatic Cancer News By Topic
Pancreatic Cancer - Screening/PreventionHigh Circulating Vitamin D Levels Don’t Reduce Risk of Less Common Cancers (7/12/2010)
High levels of vitamin D in the bloodstream do not appear to reduce the risk of seven less common cancers: endometrial, esophageal, stomach, ovarian, pancreatic, kidney, and non-Hodgkin’s lymphoma.
Soda Consumption May Be Linked to Pancreatic Cancer (2/9/2010)
Individuals who consumed two or more sugary soft drinks per week experienced a statistically significant increased risk of pancreatic cancer when compared with individuals who did not consume soft drinks, according to the results of a study conducted in Singapore and published in Cancer Epidemiology, Biomarkers, and Prevention.
Lynch Syndrome Increases Risk of Pancreatic Cancer (11/2/2009)
Lynch Syndrome, an inherited cause of colorectal cancer that also increases the risk of several other types of cancer, results in a risk of pancreatic cancer that is several times higher than the risk in the general population. These results were published in the Journal of the American Medical Association.
Blood Type Gene Linked with Pancreatic Cancer Risk (8/5/2009)
Individuals with the gene variant that results in A, B, or AB blood types appear to have a higher risk of developing pancreatic cancer than individuals with the gene variant that results in blood type O. These results were published in Nature Genetics.
Obesity Increases Pancreatic Cancer Risks (6/25/2009)
Overweight or obesity during early adulthood increases the risk of developing pancreatic cancer and is also linked with a younger age at diagnosis. Overweight or obesity later in life is linked with worse pancreatic cancer survival. These results were published in the Journal of the American Medical Association.
Pancreatic Cancer - Stages I-IIINovel Chemotherapy Regimen for Locally Advanced Pancreatic Cancer (3/30/2010)
A novel chemotherapy regimen followed by radiation appears to be safe and effective for patients with locally advanced pancreatic cancer, resulting in an overall survival of 66%. These study results were presented at the 2010 Gastrointestinal Cancers Symposium in Orlando, Florida.
Chemotherapy Improves Pancreatic Cancer Survival (9/10/2009)
Among patients with inoperable pancreatic cancer, Gemzar® (gemcitabine)-based chemotherapy results in longer survival and better quality of life than an alternative treatment regimen consisting of enzyme therapy, nutritional supplements, detoxification, and an organic diet. These results were published in the Journal of Clinical Oncology.
Pancreatic Cancer Care Is Inconsistent (7/21/2009)
The quality of care for pancreatic cancer varies considerably among hospitals in the United States, according to the results of a study published in the Journal of the National Cancer Institute.
Obesity Worsens Outcomes After Surgery for Pancreatic Cancer (3/30/2009)
According to the results of a study published in the Archives of Surgery, pancreatic caner patients with a body mass index (BMI) greater than 35 have a greater risk of recurrence and worse survival after surgery than patients with a lower BMI.
Neoadjuvant Radiation Improves Survival in Pancreatic Cancer (12/5/2008)
Preoperative radiation nearly doubles the survival rate for patients with operable pancreatic cancer, according to the results of a study published in the November 15, 2008 issue of the International Journal of Radiation Oncology Biology Physics.
Pancreatic Cancer - Stage IVGemzar plus Avastin Does Not Improve Survival in Advanced Pancreatic Cancer (7/14/2010)
Results from a recent Phase III trial indicate that the addition of the targeted therapy Avastin® (bevacizumab) to the chemotherapy drug Gemzar® (gemcitabine) does not improve survival in advanced pancreatic cancer.
Afinitor Delays Progression of Advanced Pancreatic Neuroendocrine Tumors (7/8/2010)
In a recent Phase III trial, the targeted therapy Afinitor® (everolimus) more than doubled progression-free survival time among patients with advanced pancreatic neuroendocrine tumors (NET).
Improved Survival in Metastatic Pancreatic Cancer (6/24/2010)
It appears that the chemotherapy combination known as FOLFIRINOX may improve survival in metastatic pancreatic cancer over a current standard-of-care, Gemzar® (gemcitabine).
AMG 479 Produces Promising Results in Metastatic Pancreatic Cancer (6/7/2010)
According to the results of a Phase II clinical trial, treatment of metastatic pancreatic cancer with a combination of AMG 479 and Gemzar® (gemcitabine) resulted in better progression-free and overall survival than treatment with Gemzar alone. These results were presented at the 2010 annual meeting of the American Society of Clinical Oncology.
Depression May Persist With Metastatic Cancer (5/27/2010)
A substantial number of patients with metastatic cancer may suffer from depression which tends to persist and grow more severe toward the end of life, according to the results of a study published early online in the Journal of Clinical Oncology.
Pancreatic Cancer - RecurrentNCCN Updates Pancreatic Cancer Guidelines (12/12/2007)
The National Comprehensive Cancer Network (NCCN), an alliance of 21 leading cancer centers, has updated its guidelines regarding the care of pancreatic cancer patients. The updated guidelines include a new section on supportive care and a greater emphasis on use of neoadjuvant (before surgery) therapy for patients with cancers that are borderline resectable (cancers that can possibly be surgically removed, but that run a risk of incomplete removal).
GEMOX Active in Recurrent Pancreatic Cancer (2/24/2006)
According to a an article recently published in the British Journal of Cancer, the chemotherapy combination consisting of Gemzar® (gemcitabine) plus Eloxatin® (oxaliplatin), referred to as GEMOX, has activity in the treatment of pancreatic cancer that has stopped responding to Gemzar.
Pancreatic Cancer Research Map Will Track Researchers, Studies and Funding Opportunities (5/10/2005)
The Pancreatic Cancer Research Map was first launched during Pancreatic Cancer Awareness Month in November 2004. The second phase has begun with the addition of grants from PanCAN and the Lustgarten Foundation.
Further Evidence that Rubitecan Offers Benefit for Refractory Pancreatic Cancer (12/1/2003)
According to results presented at the Chemotherapy Foundation Symposium XXI, the anticancer agent rubitecan (Orathecin™) appears to provide a treatment alternative to patients with recurrent pancreatic cancer.
Raltitrexed and Camptosar® Effective in Recurrent Pancreatic Cancer (4/27/2003)
According to an article recently published in the
British Journal of Cancer, Camptosar® plus raltitrexed demonstrates anti-cancer activity inpatients with advanced pancreatic cancer that has stopped responding to Gemzar®.
|
